Cargando…
A mark of disease: how mRNA modifications shape genetic and acquired pathologies
RNA modifications have recently emerged as a widespread and complex facet of gene expression regulation. Counting more than 170 distinct chemical modifications with far-reaching implications for RNA fate, they are collectively referred to as the epitranscriptome. These modifications can occur in all...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962492/ https://www.ncbi.nlm.nih.gov/pubmed/33376192 http://dx.doi.org/10.1261/rna.077271.120 |
_version_ | 1783665479496237056 |
---|---|
author | Destefanis, Eliana Avşar, Gülben Groza, Paula Romitelli, Antonia Torrini, Serena Pir, Pınar Conticello, Silvestro G. Aguilo, Francesca Dassi, Erik |
author_facet | Destefanis, Eliana Avşar, Gülben Groza, Paula Romitelli, Antonia Torrini, Serena Pir, Pınar Conticello, Silvestro G. Aguilo, Francesca Dassi, Erik |
author_sort | Destefanis, Eliana |
collection | PubMed |
description | RNA modifications have recently emerged as a widespread and complex facet of gene expression regulation. Counting more than 170 distinct chemical modifications with far-reaching implications for RNA fate, they are collectively referred to as the epitranscriptome. These modifications can occur in all RNA species, including messenger RNAs (mRNAs) and noncoding RNAs (ncRNAs). In mRNAs the deposition, removal, and recognition of chemical marks by writers, erasers and readers influence their structure, localization, stability, and translation. In turn, this modulates key molecular and cellular processes such as RNA metabolism, cell cycle, apoptosis, and others. Unsurprisingly, given their relevance for cellular and organismal functions, alterations of epitranscriptomic marks have been observed in a broad range of human diseases, including cancer, neurological and metabolic disorders. Here, we will review the major types of mRNA modifications and editing processes in conjunction with the enzymes involved in their metabolism and describe their impact on human diseases. We present the current knowledge in an updated catalog. We will also discuss the emerging evidence on the crosstalk of epitranscriptomic marks and what this interplay could imply for the dynamics of mRNA modifications. Understanding how this complex regulatory layer can affect the course of human pathologies will ultimately lead to its exploitation toward novel epitranscriptomic therapeutic strategies. |
format | Online Article Text |
id | pubmed-7962492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cold Spring Harbor Laboratory Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79624922021-04-01 A mark of disease: how mRNA modifications shape genetic and acquired pathologies Destefanis, Eliana Avşar, Gülben Groza, Paula Romitelli, Antonia Torrini, Serena Pir, Pınar Conticello, Silvestro G. Aguilo, Francesca Dassi, Erik RNA Review RNA modifications have recently emerged as a widespread and complex facet of gene expression regulation. Counting more than 170 distinct chemical modifications with far-reaching implications for RNA fate, they are collectively referred to as the epitranscriptome. These modifications can occur in all RNA species, including messenger RNAs (mRNAs) and noncoding RNAs (ncRNAs). In mRNAs the deposition, removal, and recognition of chemical marks by writers, erasers and readers influence their structure, localization, stability, and translation. In turn, this modulates key molecular and cellular processes such as RNA metabolism, cell cycle, apoptosis, and others. Unsurprisingly, given their relevance for cellular and organismal functions, alterations of epitranscriptomic marks have been observed in a broad range of human diseases, including cancer, neurological and metabolic disorders. Here, we will review the major types of mRNA modifications and editing processes in conjunction with the enzymes involved in their metabolism and describe their impact on human diseases. We present the current knowledge in an updated catalog. We will also discuss the emerging evidence on the crosstalk of epitranscriptomic marks and what this interplay could imply for the dynamics of mRNA modifications. Understanding how this complex regulatory layer can affect the course of human pathologies will ultimately lead to its exploitation toward novel epitranscriptomic therapeutic strategies. Cold Spring Harbor Laboratory Press 2021-04 /pmc/articles/PMC7962492/ /pubmed/33376192 http://dx.doi.org/10.1261/rna.077271.120 Text en © 2021 Destefanis et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society http://creativecommons.org/licenses/by/4.0/ This article, published in RNA, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Destefanis, Eliana Avşar, Gülben Groza, Paula Romitelli, Antonia Torrini, Serena Pir, Pınar Conticello, Silvestro G. Aguilo, Francesca Dassi, Erik A mark of disease: how mRNA modifications shape genetic and acquired pathologies |
title | A mark of disease: how mRNA modifications shape genetic and acquired pathologies |
title_full | A mark of disease: how mRNA modifications shape genetic and acquired pathologies |
title_fullStr | A mark of disease: how mRNA modifications shape genetic and acquired pathologies |
title_full_unstemmed | A mark of disease: how mRNA modifications shape genetic and acquired pathologies |
title_short | A mark of disease: how mRNA modifications shape genetic and acquired pathologies |
title_sort | mark of disease: how mrna modifications shape genetic and acquired pathologies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962492/ https://www.ncbi.nlm.nih.gov/pubmed/33376192 http://dx.doi.org/10.1261/rna.077271.120 |
work_keys_str_mv | AT destefaniseliana amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT avsargulben amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT grozapaula amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT romitelliantonia amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT torriniserena amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT pirpınar amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT conticellosilvestrog amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT aguilofrancesca amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT dassierik amarkofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT destefaniseliana markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT avsargulben markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT grozapaula markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT romitelliantonia markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT torriniserena markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT pirpınar markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT conticellosilvestrog markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT aguilofrancesca markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies AT dassierik markofdiseasehowmrnamodificationsshapegeneticandacquiredpathologies |